Literature DB >> 19410623

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.

B Camilloni1, M Neri, E Lepri, A M Iorio.   

Abstract

This study evaluated whether MF59-adjuvanted subunit trivalent influenza vaccine for the 2003/04 winter season (A/Moscow/10/99, H3N2; A/New Caledonia/20/99, H1N1; B/Hong Kong/330/01) would confer protection against mismatched and frequently co-circulating variants of influenza B/Victoria- and B/Yamagata-like virus strains. Haemagglutination inhibiting (HI) antibodies were measured in middle-aged and elderly volunteers against the homologous B/Victoria-like vaccine strain (B/Hong Kong/330/01) and against mismatched B/Victoria-like (B/Malaysia/2506/04) and B/Yamagata-like (B/Singapore/379/99 and B/Shanghai/361/02) strains. Immunization induced significant increases in the amounts of HI antibodies against all influenza B strains under investigation. However, the responses against the heterologous B/Shanghai/361/02 virus did not reach the desirable values of seroprotection. An age-dependent decline of the responses was found for B/Victoria-like antigens, but not for B/Yamagata-like strains. Although further studies are needed, our data support the recommendation of including influenza B viruses of the B/Victoria and B/Yamagata lineages in the future influenza vaccine preparations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410623     DOI: 10.1016/j.vaccine.2009.04.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

2.  Stimulation of protective and cross-protective immunity against influenza B virus after adjuvant mucosal immunization of mice.

Authors:  L Prokesová; P Zanvit; M Havlícková; J Tácner; M Jirkovská; P Petrásková; O Novotná; D Cechová; J Julák
Journal:  Folia Microbiol (Praha)       Date:  2010-02-07       Impact factor: 2.099

Review 3.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI).

Authors: 
Journal:  J Prev Med Hyg       Date:  2019-10-15

5.  Potential impact of B lineage mismatch on trivalent influenza vaccine effectiveness during the 2015-2016 influenza season among nursery school children in Suzhou, China.

Authors:  Yin Wang; Liling Chen; Yuejia Cheng; Suizan Zhou; Yuanyuan Pang; Jun Zhang; Carolyn M Greene; Ying Song; Tao Zhang; Genming Zhao
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

6.  A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.

Authors:  Keith S Reisinger; Sandra J Holmes; Paola Pedotti; Ashwani Kumar Arora; Maria Lattanzi
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Molecular Detection of Influenza A and B Viruses in Four Consecutive Influenza Seasons 2015-16 to 2018-19 in a Tertiary Center in Western Saudi Arabia.

Authors:  Abdulhakeem Althaqafi; Fayssal Farahat; Asim Alsaedi; Majid Alshamrani; Moneerah S Alsaeed; Baraa AlhajHussein; Sherif A El-Kafrawy; Esam I Azhar
Journal:  J Epidemiol Glob Health       Date:  2021-05-04

Review 8.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

9.  Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK.

Authors:  Anke L Stuurman; Sara Ciampini; Alfredo Vannacci; Antonino Bella; Caterina Rizzo; Cintia Muñoz-Quiles; Elisabetta Pandolfi; Harshana Liyanage; Mendel Haag; Monika Redlberger-Fritz; Roberto Bonaiuti; Philippe Beutels
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

10.  Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

Authors:  Jiří Beran; Mathieu Peeters; Walthère Dewé; Jolana Raupachová; Lenka Hobzová; Jeanne-Marie Devaster
Journal:  BMC Infect Dis       Date:  2013-05-20       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.